Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleEfficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.
Author(s)Berman JS, Symonds C, Birch R.
Journal, Volume, IssuePain. 2004 ;112(3):299-306.
Major outcome(s)Significant pain relief and improvement of sleep

The objective was to investigate the effectiveness of cannabis-based medicines
for treatment of chronic pain associated with brachial plexus root avulsion.
This condition is an excellent human model of central neuropathic pain as it
represents an unusually homogenous group in terms of anatomical location of
injury, pain descriptions and patient demographics. Forty-eight patients with at
least one avulsed root and baseline pain score of four or more on an 11-point
ordinate scale participated in a randomised, double-blind, placebo-controlled,
three period crossover study. All patients had intractable symptoms regardless
of current analgesic therapy. Patients entered a baseline period of 2 weeks,
followed by three, 2-week treatment periods during each of which they received
one of three oromucosal spray preparations. These were placebo and two whole
plant extracts of Cannabis sativa L.: GW-1000-02 (Sativex((R))), containing
Delta(9)tetrahydrocannabinol (THC):cannabidiol (CBD) in an approximate 1:1 ratio
and GW-2000-02, containing primarily THC. The primary outcome measure was the
mean pain severity score during the last 7 days of treatment. Secondary outcome
measures included pain related quality of life assessments. The primary outcome
measure failed to fall by the two points defined in our hypothesis. However,
both this measure and measures of sleep showed statistically significant
improvements. The study medications were generally well tolerated with the
majority of adverse events, including intoxication type reactions, being mild to
moderate in severity and resolving spontaneously. Studies of longer duration in
neuropathic pain are required to confirm a clinically relevant, improvement in
the treatment of this condition.

Dose(s)2,5 mg THC per spray, average 9.2 sprays with THC
Duration (days)14
Participants48 with neuropathic pain from brachial plexus avulsion
DesignControlled study
Type of publicationMedical journal
Address of author(s)Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex HA7 4LP, UK.
Full text

[Back to Overview]  [IACM Homepage]